Drug-induced liver injury in the elderly

Current Gastroenterology Reports

Volumn 15, Issue 1, 2013, Pages

  Stine, Jonathan G ^a   Sateesh, Praveen ^a   Lewis, James H ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Drug safety; Drug induced liver injury; Elderly; Hepatotoxicity; Polypharmacy

Indexed keywords

ANTIBIOTIC AGENT; BENOXAPROFEN; CARDIOVASCULAR AGENT; DICLOFENAC; HERBACEOUS AGENT; ISONIAZID; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROPYLTHIOURACIL; RIFAMPICIN; TUBERCULOSTATIC AGENT; VALPROIC ACID;

ADVERSE OUTCOME; AGE; ARTICLE; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; EPIDEMIOLOGICAL DATA; HEPATITIS; HIGH RISK POPULATION; HUMAN; INCIDENCE; KIDNEY FAILURE; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; NONHUMAN; OBSTRUCTIVE JAUNDICE; PHARMACODYNAMICS; POLYPHARMACY; PRESCRIPTION; PREVALENCE; RISK FACTOR; SEX DIFFERENCE; TOXIC HEPATITIS; AGED; DRUG INTERACTION; FEMALE; INAPPROPRIATE PRESCRIBING; MALE; PATHOPHYSIOLOGY; REVIEW;

AGE FACTORS; AGED; DRUG INTERACTIONS; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; INAPPROPRIATE PRESCRIBING; MALE; POLYPHARMACY; RISK FACTORS; SEX FACTORS;

EID: 84871153968     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-012-0299-8     Document Type: Article

References (64)

1. Zimmerman HJ. Hepatotoxocity: The adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, William & Wilkins; 1999.
2. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs: II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46:1331-6. (Pubitemid 23333874)
3. Herlinger C, Klotz U. Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol. 2001;15(6):897-918. (Pubitemid 34110600)
4. Kitani K. Aging of the liver: facts and theories. Arch Gerontol Geriatr. 1991;12:133-54.
5. Triantafyllou K, Vlachogiannakos J, Ladas SD. Gastrointestinal and liver side effects of drugs in elderly patients. Best Pract Res Clin Gastroenterol. 2010;24(2):203-15.
6. DeLeve L. Risk factors for drug-induced liver disease Drug-Induced Liver Disease. New York: Informa Healthcare USA, Inc; 2007. p. 291-305.
7. Chalasani N, Björnsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010;138(7):2246-59.
8. Ghabril M, Chalasani N, Bjornsson E. "Drug-induced liver injury: a clinical update". Curr Opin Gastroenterol. 2010;26:222-6.
9. Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Semin Liver Dis. 2009;29(4):400-11.
10. Liss G, Rattan S, Lewis JH. Predicting and preventing acute drug-induced liver injury: what's new in 2010? Expert Opin Drug Metab Toxicol. 2010;6(9):1047-61.
11. census.gov.
12. FDA.gov. "Guidelines for Industry. Studies in Support of Special Populations: Geriatrics". www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm073131.pdf. This paper is important because it provides the most up-to-date guidance from the FDA for seeking out elderly patients in partnership with new drug development and testing.
13. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163:2716-24. (Pubitemid 37517412)
14. Gallagher P, Barry P, O'Mahony D. Inappropriate prescribing in the elderly. J Clin Pharm Ther. 2007;32(2):113-21. (Pubitemid 46449699)
15. Blalock SJ, Byrd JE, Hansen RA, et al. Factors associated with potentially inappropriate drug utlizization in a sample of rural community-dwelling older adults. Am J Geriatr Pharmacother. 2005;3(3):168-79. (Pubitemid 41644455)
16. Sawyer P, Bodner EV, Ritchie CS, et al. Pain and pain medication use in community-dwelling older adults. Am J Geriatr Pharmacother. 2006;4(4):316-24. (Pubitemid 46211184)
17. Crentsil V, Ricks MO, Xue QL, et al. A pharmacoepidemiologic study of community-dwelling disabled older women: Factors associated with medication use. Am J Geriatr Pharmacother. 2010;8(3):215-24.
18. Junius-Walker U, Theile G, Hummers-Pradler E. Prevalence and predictors of polypharmacy among older primary care patients in Germany. Fam Pract. 2007;24(1):14-9. (Pubitemid 46454660)
19. Yoon SL, Schaffer SD. Herbal, prescribed and over-the-counter drug use in older women: prevalence of drug interactions. Geriatr Nurs. 2006;27(2):118-29. (Pubitemid 43586185)
20. Lucena MI, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatol. 2009;49:2001-9. This study questions the notion that age alone predetermines the type of idiosyncratic drug injury and suggests that sex has a role in determining hepatocellular versus cholestatic injury patterns.
21. Lammert C, et al. Oral medications with significant hepatic metabolism at higher risk for adverse events. Hepatol. 2010;51:615-20.
22. Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010;138(7):2246-59.
23. Woodhouse K, Wynne HA. Age-related changes in hepatic function. Implications in drug therapy. Drug Aging. 1992;2:243-55.
24. Wynne H, Cope L, Mutch E, et al. The effect of age upon liver size and liver blood flow in man. Hepatology. 1989;9:297-301. (Pubitemid 19063317)
25. Mooney H, Roberts R, Cooksley WGE, et al. Alterations in the liver with aging. Clin Gastroenterol. 1985;14:757-71.
26. Le Couter DG, Cogger VC, Markus AM, et al. Pseudocapillarisation and associated energy limitation in the aged rat liver. Hepatology. 2001;33:537-43. (Pubitemid 32185214)
27. Le Couter DG, Fraser R, Cogger VC, et al. Hepatic pseuodcapillarisation and atherosclerosis in ageing. Lancet. 2002;359:1612-5. (Pubitemid 34621132)
28. Lewis JH. Drug-induced liver disease. Med Clin North Am. 2000;84(5):1275-311.
29. Benhamou JP. Drug-induced hepatitis: clinical aspects. In: Fillastre JP, editor. Hepatotoxicity of drugs. Rouen: University of Rouen; 1986. p. 23-30.
30. Onji M, Fujioka S, Takeuchi Y, et al. Clinical characteristics of drug-induced liver injury in the elderly. Hepatol Res. 2009;39:546-52. This Japanese study shows that, of the patients admitted for drug-induced hepatitis, roughly half were elderly.
31. Andrade RJ, Lucena MI, Fernandez C, et al. Drug induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512-21. (Pubitemid 41096639)
32. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug induced liver disease. Hepatology. 2005;42:481-9. (Pubitemid 41061102)
33. Chalassani N, Fonatana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135:1924-34. This comprehensive American study shows a slightly lower incidence than the Japanese study; however, roughly one in five patients with drug-induced liver injury included in the study were in fact elderly.
34. Devarbhavi H, Dierkhising R, Kremers WK, et al. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol. 2010;105(11):2396-404.
35. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947-54. (Pubitemid 35440240)
36. Reuben A, Koch DG, Lee WM, et al. Drug-induced acute liver failure: results of a U.S. multicenter prospective study. Hepatology. 2010;52:2065-76.
37. Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis. 2009;29:337-47.
38. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug induced hepatic injuries: a French population-based study. Hepatology. 2002;36(2):451-5. (Pubitemid 34810366)
39. Lucena MI, Andrade RJ, Fernandez MC, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology. 2006;44(4):850-6. (Pubitemid 46489548)
40. Banks AT, Zimmerman HJ, Ishak KG, et al. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology. 1995;22(3):820-7.
41. Lee WM, Larrey D, Olsson R, et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf. 2005;28(4):351-70. (Pubitemid 40545769)
42. Primeggia J, Lewis JH. Gone (From the Physicians' Desk Reference) but not forgotten: propylthiouracil-associated hepatic failure: a call for liver test monitoring. J National Med Assoc. 2010;102(6):531-4.
43. Teitelbaum JE, Perez-Atayade AR, Cohen M, et al. Minocycline-related autoimmune hepatitis: case series and literature review. Arch Pediatr Adolesc Med. 1998;152(11):1132-6. (Pubitemid 28509394)
44. Squires Jr RHJ, Shneider BL, Bucuvalas J, et al. Acute liver failure in children: the first 348 patient in the pediatric acute liver failure study group. J Pediatr. 2006;148(5):652-8. (Pubitemid 43792501)
45. Taggart HM, Alderdice JM. Fatal cholestatic jaundice in elderly patients taking benoxaprofen. Br Med J. 1982;284(6326):1372.
46. van den Brande P, van Steernbergen W, Verboort G, et al. Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis. Am J Respir Crit Care Med. 1995;152(5 Pt 1):1705-8.
47. Snider Jr DE, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis. 1992;145(2 Pt 1):494-7.
48. Kunst H, Khan KS. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. Int J Tuberc Lung Dis. 2010;14(11):1374-81.
49. Singla R, Sharma SK, Mohan A, et al. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res. 2010;132:81-6. This recent, large case-control study confirms the previous work of Zimmerman amongst others showing that age is an independent predictor of drug-induced liver injury with anti-TB drugs.
50. Huang YS, Chern HD, Su WJ. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology. 2002;35(4):883-9. (Pubitemid 34258383)
51. Lee SW, Chung LS, Huang HH, et al. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis. 2010;14(5):622-6.
52. Possuelo LG, Castelan JA, de Brito TC, et al. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol. 2008;64(7):673-81.
53. Lewis JH. Nonsteroidal Anti-inflammatory drugs and leukotriene receptor antagonists: Pathology and clinical presentation of hepatotoxicity." Drug-Induced Liver Disease. New York: Informa Healthcare USA, Inc; 2007. p. 439-64.
54. Halsey J, Cardoe N. Benoxaprofen: side effect profile in 300 patients. Br Med J (Clin Red Ed). 1982;284:1385-8.
55. Prescott LE, Leslie PJ, Padfield P. Side effects of benoxaprofen. Br Med J. 1982;284:1782.
56. Lewis JH, Zimmerman JH. Drug- and chemical- induced cholestasis. Clin Liver Dis. 1999;3:433-64.
57. Hamdy RC, Murnane B, Perera N, et al. The pharmacokinetics of benoxaprofen in elderly subjects. Eur J Rheumatol Inflamm. 1982;5:69-76.
58. Mohi-ud-din R, Lewis JH. Drug- and chemical-induced cholestasis. Clin Liver Dis. 2004;8:95-132. (Pubitemid 38373672)
59. Mindikoglu AL, Magder LS, Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. Liver Trasnpl. 2009;15(7):719-29.
60. Junius-Walker U, Theile G, Hummers-Pradier E. Prevalence and predictors of polypharmacy among older primary care patients in Germany. Fam Pract. 2007;24(1):14-9. (Pubitemid 46454660)
61. Tulner LR, Kuper IM, Frankfort SV, et al. Discrepancies in reported drug use in geriatric outpatients: relevance to adverse events and drug-drug interactions. Am J Geriatr Pharmacother. 2009;7(2):93-104. This Dutch study illustrates the degree of polypharmacy the elderly are subject to, with three-quarters of their patient population on at least 4 drugs.
62. Canter PH, Ernst E. Herbal supplement use by persons aged over 50 years in Britain: frequently used herbs, concomitant use of herbs, nutritional supplements and prescription drugs, rate of informing doctors and potential for negative interactions. Drugs Aging. 2004;21(9):597-605. (Pubitemid 39070994)
63. Dwyer LL, Han B, Woodwell DA. Polypharmacy in nursing home residents in the United States: results of the 2004 National Nursing Home Survey. Am J Geriatr Pharmacother. 2010;8(1):63-72. This study illustrates the continuing problem of polypharmacy in institution-dwelling elderly patients, suggesting these patients are the most at-risk group for drug-induced liver injury.
64. Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis. 2007;11(3):477-505. (Pubitemid 47302343)